Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 04 2025
0mins
Source: Globenewswire
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, aiming to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash reserves expected to support operations through anticipated clinical readouts into 2028.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
